Management

Concert has built a dynamic management team with broad expertise in drug development and operational excellence.

• Roger Tung, Ph.D., President and CEO
• Nancy Stuart, Chief Operating Officer
• Robert Silverman, J.D., Ph.D., Vice President and General Counsel
• Robert Zelle, Ph.D., Vice President, Drug Development

Biographies of the Concert management team are available to download as a PDF.

Roger Tung, Ph.D., Co-Founder, President and CEO

Dr. Roger Tung, President and Chief Executive Officer of Concert Pharmaceuticals, Inc., co-founded the Company in April 2006 based on research he carried out as an independent scientist. Before Concert, Dr. Tung worked in venture-backed start-up and major pharmaceutical companies, including Vertex Pharmaceuticals Inc., where he was a founding scientist; Merck, Sharp and Dohme; and E.R. Squibb & Sons. At Vertex, Dr. Tung most recently served as Vice President of Drug Discovery at its San Diego site. He co-invented and headed discovery of Vertex’s two commercial HIV protease inhibitor products, Lexiva® and Agenerase®, and led development of Agenerase, in collaboration with Glaxo, through FDA and EMEA approval. Dr. Tung has overseen the discovery of numerous other clinical candidates. He has published widely and has been granted 47 U.S. patents. Dr. Tung received his Ph.D. in Medicinal Chemistry at the University of Wisconsin-Madison from Professor Daniel H. Rich.

[ back to top ]

Nancy Stuart, Chief Operating Officer

Ms. Nancy Stuart has over 20 years of biotechnology and pharmaceutical industry experience and currently serves as Chief Operating Officer of Concert Pharmaceuticals, Inc.  Prior to joining Concert in July 2006, she held senior level business and drug development positions at RRD International, Scion Pharmaceuticals, Kinetix/Amgen Inc., Vertex Pharmaceuticals, Inc. and Genzyme Corporation.  At Kinetix, Ms. Stuart established the business development strategy that culminated in its $170 million acquisition by Amgen.  At Vertex, she served as Vice President of Program Planning and Management and was responsible for Vertex’s strategic partnerships and global drug development programs. In addition, she co-directed the development of Agenerase®, Vertex’s HIV protease inhibitor and initiated the Thyrogen® program for thyroid cancer testing at Genzyme. She has had extensive experience in raising private capital for start up biotechnology companies. Ms. Stuart is a member of the Board of Directors for the YMCA of Greater Boston. She holds a Bachelor of Science from the University of Michigan, and an MBA from the Simmons College Graduate School of Management.

[ back to top ]

Robert Silverman, J.D., Ph.D., Vice President and General Counsel

Dr. Robert Silverman joined Concert Pharmaceuticals, Inc. as Vice President and General Counsel in January 2007 with over 20 years legal and scientific experience.  Before Concert, he served as Associate General Counsel at Millennium Pharmaceuticals, Inc., where he was primarily responsible for developing and leading the company’s chemical patent practice. Prior to his tenure at Millennium, he was a senior patent attorney at Vertex Pharmaceuticals, Inc. where he played a major role in building its patent department.  Before Vertex, Dr. Silverman held positions of increasing responsibility in the law department of FMC Corporation where he became Group Patent Counsel overseeing intellectual property matters for multiple chemical businesses.  He was also a senior research chemist at FMC before joining its law department.  Dr. Silverman received his J.D. from Rutgers-Camden Law School.  He also has an undergraduate degree from Lehigh University, a Ph.D. in organic chemistry from the University of New Mexico and conducted postdoctoral research in chemistry at Stanford University.

[ back to top ]

Robert Zelle, Ph.D., Vice President, Drug Development

Dr. Robert Zelle has over 20 years of drug discovery and development experience and currently serves as Vice President, Drug Development of Concert Pharmaceuticals, Inc.  Prior to joining Concert in July 2006 he held key positions at Scion Pharmaceuticals, Acusphere, Vertex Pharmaceuticals and Abbott Laboratories.  Before Concert, Dr. Zelle founded Bell Rock Associates, a pharmaceutical development consulting firm.  He also served as Vice President of Chemistry at Scion where he was responsible for discovery chemistry, manufacturing, intellectual property and regulatory submissions.  Before Scion, he was Senior Director of Regulatory Affairs and Product Development at Acusphere.  In this role he was responsible for regulatory affairs, quality assurance, quality control and preclinical testing. Dr. Zelle has been granted 24 U.S. patents with numerous pending U.S. applications.  Dr. Zelle has had extensive experience filing investigational new drug (IND) applications and bringing compounds into clinical development.  He was an NIH postdoctoral fellow with Professor Samuel Danishefsky at Yale University.  He received his Ph.D. in organic chemistry at Indiana University from Professor Paul Grieco.

[ back to top ]